X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3089) 3089
Book Review (415) 415
Publication (339) 339
Magazine Article (11) 11
Conference Proceeding (10) 10
Book Chapter (4) 4
Trade Publication Article (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2766) 2766
humans (2544) 2544
adenine - analogs & derivatives (1923) 1923
male (1483) 1483
female (1415) 1415
tenofovir (1347) 1347
organophosphonates - administration & dosage (1282) 1282
organophosphonates - therapeutic use (1077) 1077
adult (1068) 1068
adenine - administration & dosage (1064) 1064
adenine - therapeutic use (957) 957
middle aged (808) 808
animals (790) 790
antiviral agents - therapeutic use (786) 786
hiv infections - drug therapy (739) 739
cytosine - analogs & derivatives (734) 734
infectious diseases (679) 679
antiviral agents - administration & dosage (665) 665
organophosphonates (652) 652
pharmacology & pharmacy (630) 630
treatment outcome (603) 603
drug therapy, combination (590) 590
anti-hiv agents - administration & dosage (564) 564
organophosphonates - adverse effects (506) 506
adenine - adverse effects (487) 487
organophosphonates - pharmacology (484) 484
hepatitis b, chronic - drug therapy (467) 467
virology (437) 437
deoxycytidine - analogs & derivatives (434) 434
anti-hiv agents - therapeutic use (432) 432
emtricitabine (430) 430
immunology (411) 411
cytosine - therapeutic use (409) 409
hiv (400) 400
cidofovir (399) 399
cytosine - administration & dosage (398) 398
aids/hiv (387) 387
lamivudine (387) 387
drug therapy (364) 364
antiviral agents (356) 356
infection (342) 342
lamivudine - therapeutic use (337) 337
therapy (328) 328
deoxycytidine - administration & dosage (307) 307
viral load (299) 299
anti-hiv agents - adverse effects (287) 287
organophosphorus compounds - therapeutic use (283) 283
hepatitis b (280) 280
reverse transcriptase inhibitors - administration & dosage (277) 277
adenine - pharmacology (272) 272
aged (271) 271
health aspects (271) 271
lamivudine - administration & dosage (271) 271
human immunodeficiency virus--hiv (269) 269
abridged index medicus (268) 268
mice (265) 265
drug administration schedule (259) 259
reverse transcriptase inhibitors - therapeutic use (258) 258
drug resistance, viral (255) 255
hiv infections - prevention & control (255) 255
antiviral agents - pharmacology (253) 253
organophosphonates - pharmacokinetics (252) 252
organophosphorus compounds - administration & dosage (251) 251
adolescent (245) 245
microbiology (242) 242
adenine - pharmacokinetics (235) 235
antiviral agents - adverse effects (228) 228
adefovir dipivoxil (227) 227
rats (223) 223
dosage and administration (222) 222
gastroenterology & hepatology (221) 221
young adult (220) 220
hepatitis b virus - drug effects (219) 219
hiv infections - virology (219) 219
virus diseases (218) 218
time factors (216) 216
hiv infection (212) 212
antiretroviral therapy (211) 211
pharmacokinetics (211) 211
efficacy (208) 208
guanine - analogs & derivatives (205) 205
hiv-1 - drug effects (205) 205
adefovir (204) 204
prevention (203) 203
hepatitis b virus - genetics (202) 202
deoxycytidine - therapeutic use (200) 200
administration, oral (196) 196
aids (192) 192
antiretroviral drugs (191) 191
care and treatment (191) 191
dose-response relationship, drug (190) 190
drug combinations (189) 189
research (189) 189
mutation (186) 186
hepatitis b, chronic - virology (185) 185
analysis (183) 183
safety (182) 182
organophosphonates - chemistry (177) 177
hepatitis b virus (164) 164
infections (164) 164
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2912) 2912
German (46) 46
Spanish (38) 38
Chinese (27) 27
French (23) 23
Russian (14) 14
Japanese (12) 12
Korean (8) 8
Polish (6) 6
Hungarian (5) 5
Dutch (3) 3
Italian (2) 2
Turkish (2) 2
Bulgarian (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TREATMENT-NAIVE | PHARMACOKINETICS | RALTEGRAVIR | SAFETY | EFAVIRENZ | ADULTS | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | ADHERENCE | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Inhibitors | Protease inhibitors | Interactive systems | Index Medicus | Abridged Index Medicus
Journal Article
Science, ISSN 0036-8075, 9/2010, Volume 329, Issue 5996, pp. 1168 - 1174
The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of... 
Human sexual behavior | HIV infections | Antiinfectives | Gels | HIV | RESEARCH ARTICLES | Placebos | Experimentation | AIDS | Infections | Condoms | VAGINAL GEL | INDIVIDUALS | SOUTH-AFRICA | PROPHYLAXIS | IN-VITRO | TRANSMISSION | MULTIDISCIPLINARY SCIENCES | CLINICAL-TRIALS | MALE CIRCUMCISION | RANDOMIZED CONTROLLED-TRIAL | CHALLENGES | HIV Infections - prevention & control | Anti-Infective Agents, Local - therapeutic use | Urban Population - statistics & numerical data | HIV Infections - epidemiology | Humans | Anti-Infective Agents, Local - adverse effects | Drug Resistance, Viral | Administration, Intravaginal | Viral Load | Incidence | Anti-HIV Agents - administration & dosage | Tenofovir | Young Adult | Adenine - adverse effects | HIV-1 - physiology | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Vaginal Creams, Foams, and Jellies | Rural Population - statistics & numerical data | Sexual Behavior | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | South Africa - epidemiology | Organophosphonates - adverse effects | Adenine - administration & dosage | Pregnancy | Organophosphonates - administration & dosage | Anti-Infective Agents, Local - administration & dosage | Adolescent | Patient Compliance | Pregnancy Outcome | Prevention | Anti-infective agents | Research | HIV infection | Index Medicus
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes | Index Medicus | Abridged Index Medicus
Journal Article
AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy | Index Medicus | AIDS/HIV
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2015, Volume 372, Issue 6, pp. 509 - 518
Preventing HIV-1 infection is a high global priority. This study assessed prevention strategies in young women in South Africa, Uganda, and Zimbabwe using oral... 
TRIALS | MEDICINE, GENERAL & INTERNAL | TRANSMISSION | ANTIRETROVIRAL PROPHYLAXIS | MICROBICIDE | PREVENTION | ADHERENCE | GEL | HIV Infections - prevention & control | Humans | Middle Aged | Drug Resistance, Viral | Administration, Intravaginal | Deoxycytidine - blood | Adenine - blood | Tenofovir | Young Adult | Adenine - adverse effects | Adult | Deoxycytidine - adverse effects | Female | Organophosphonates - blood | Surveys and Questionnaires | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | HIV Seropositivity | Administration, Oral | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Anti-Retroviral Agents - adverse effects | Organophosphonates - adverse effects | Africa South of the Sahara | Adenine - administration & dosage | Pre-Exposure Prophylaxis | Organophosphonates - administration & dosage | Medication Adherence | Anti-Retroviral Agents - administration & dosage | Adolescent | HIV Infections - complications | Deoxycytidine - analogs & derivatives | Women | Care and treatment | HIV infection in women | Dosage and administration | HIV infection | Health aspects | Risk factors | Intervention | Creatinine | Antiretroviral drugs | Motivation | Human immunodeficiency virus--HIV | Prophylaxis | Vagina | Infections | Preventive medicine | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2439 - 2448
Summary Background The integrase inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and... 
Internal Medicine | NON-INFERIORITY | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | RALTEGRAVIR | TREATMENT-EXPERIENCED PATIENTS | DISOPROXIL FUMARATE | ADULTS | ANTIRETROVIRAL THERAPY | SINGLE-TABLET REGIMEN | RILPIVIRINE | TREATMENT-NAIVE PATIENTS | Emtricitabine | HIV-1 | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Deoxycytidine - administration & dosage | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Adenine - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Adult | Female | HIV Infections - drug therapy | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Clinical trials | Antiretroviral drugs | Pharmaceutical industry | Human immunodeficiency virus--HIV | Creatinine | Integrase | Laboratories | Data processing | Infections | Nausea | Ribonucleic acid--RNA | Patients | Efavirenz | Dreams | Sleep disorders | Hepatitis | Dyspnea | Inhibitors | Protease inhibitors | Insomnia | Suicides & suicide attempts | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2008, Volume 52, Issue 7, pp. 569 - 576
Objectives: This study evaluated the effects of 3 class-sparing antiretroviral therapy (ART) regimens on endothelial function in human immunodeficiency virus... 
endothelial function | human immunodeficiency virus | cardiovascular disease risk | antiretroviral therapy | CELLS | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | MYOCARDIAL-INFARCTION | GUIDELINES | TASK-FORCE | DISEASE | DYSFUNCTION | HIV-1 INFECTION | CARDIOVASCULAR RISK | RITONAVIR | HIV-1 | Lamivudine - administration & dosage | Prospective Studies | Humans | Endothelium, Vascular - drug effects | Male | Stavudine - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Time Factors | Adult | Brachial Artery - physiopathology | Female | Brachial Artery - drug effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Ritonavir - administration & dosage | Lopinavir | CD4 Lymphocyte Count | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Endothelium, Vascular - pathology | HIV Infections - drug therapy | Pyrimidinones - administration & dosage | HIV Infections - physiopathology | Studies | Ultrasonic imaging | Human immunodeficiency virus--HIV | Deflation | Aging | Clinical trials | Infections | Diabetes | Drug therapy | Risk factors | Cholesterol | Veins & arteries | Index Medicus | Abridged Index Medicus
Journal Article